Patents by Inventor Andrew Mercer
Andrew Mercer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911556Abstract: Some illustrative embodiments of an instillation assembly for treating a tissue site may include a fluid distribution lumen and a fluid hub that may define a fluid instillation pathway. The fluid distribution lumen may be defined by a first film layer and a second film layer, and the fluid hub may be positioned in fluid communication with the fluid distribution lumen. The instillation assembly may be used in combination with a reduced-pressure assembly that may define a reduced-pressure pathway separate from the fluid instillation pathway.Type: GrantFiled: June 3, 2020Date of Patent: February 27, 2024Assignee: 3M Innovative Properties CompanyInventors: David Richard Mercer, Christopher Brian Locke, Benjamin Andrew Pratt
-
Publication number: 20240018524Abstract: The present disclosure provides methods and compositions relating to gene therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting Grik2 mRNA. In particular, the present disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuit.Type: ApplicationFiled: July 9, 2021Publication date: January 18, 2024Inventors: Valérie CREPEL, Christophe MULLE, Céline BOILEAU, Séverine DEFORGES, Olivier DANOS, Andrew MERCER, Richard PORTER, April R. TEPE
-
Publication number: 20230381341Abstract: The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins that have a tropism for ocular tissue. The rAAVs have capsids that have enhanced or increased transduction of ocular tissues as compared to reference rAAVs. Such rAAVs may be useful in delivering transgenes encoding therapeutic proteins for the treatment of ocular disease.Type: ApplicationFiled: October 7, 2021Publication date: November 30, 2023Inventors: Joseph Bruder, Xu Wang, Wei-Hua Lee, Elad Firnberg, Samantha Yost, Andrew Mercer, Ye Liu, Olivier Danos, April R. Tepe
-
Publication number: 20230374541Abstract: The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences and/or amino acid substitutions that confer and/or enhance desired properties, particularly increased transduction in CNS or muscle cells relative to a rAAV having a reference capsid.Type: ApplicationFiled: October 7, 2021Publication date: November 23, 2023Inventors: Olivier Danos, Samantha Yost, Andrew Mercer, Ye Liu, Joseph Bruder, Subha Karumuthil-Melethil, Elad Firnberg, Randolph Qian, April R. Tepe, Jennifer M. Egley
-
Publication number: 20230323366Abstract: The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA.Type: ApplicationFiled: July 9, 2021Publication date: October 12, 2023Inventors: Céline BOILEAU, Valérie CREPEL, Séverine DEFORGES, Julie MASANTE, Christophe NULLE, Angélique PERET, Olivier DANOS, Andrew MERCER
-
Publication number: 20230304022Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: ApplicationFiled: September 23, 2022Publication date: September 28, 2023Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
-
Publication number: 20230227829Abstract: The present disclosure provides methods and compositions relating to gene therapy for treating epilepsy, such as a temporal lobe epilepsy, in a subject in need thereof by targeting Grik2 mRNA. In particular, the present disclosure provides inhibitory RNA constructs capable of inhibiting expression of GluK2 protein and inhibiting epileptiform discharges in hyperexcitable neuronal circuit.Type: ApplicationFiled: January 13, 2023Publication date: July 20, 2023Inventors: Valérie CREPEL, Christophe MULLE, Céline BOILEAU, Séverine DEFORGES, Olivier DANOS, Andrew MERCER, Richard PORTER, April R. TEPE
-
Publication number: 20230039652Abstract: The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA.Type: ApplicationFiled: June 30, 2022Publication date: February 9, 2023Inventors: Valérie CREPEL, Christophe Mulle, Céline Boileau, Julie Masante, Séverine Deforges, Angélique Peret, Olivier Danos, Andrew Mercer
-
Patent number: 11466277Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: GrantFiled: September 24, 2020Date of Patent: October 11, 2022Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, Andrew Mercer, Brian M. Lamb, Thomas Gaj
-
Publication number: 20220251567Abstract: The present disclosure relates to gene therapy targeting GluK2 subunit that can be used to inhibit epileptiform discharges. Short interfering RNA sequences against the human Grik2 gene sequence are described which are efficient in decreasing the expression of GluK2-containing KARs in neurons engineered to express the equivalent shRNA or miRNA. Using a tissue culture model of TLE, the examples remarkably demonstrate that viral expression of shRNA or miRNA inhibits the frequency of epileptiform discharges. Therefore, RNA therapeutics aimed at decreasing the expression of GluK2-containing KARs in neurons can remarkably prevent spontaneous epileptiform discharges in TLE. In particular, the present disclosure relates to a recombinant antisense oligonucleotide that targets a Grik2 mRNA.Type: ApplicationFiled: July 10, 2020Publication date: August 11, 2022Inventors: Valérie CREPEL, Christophe MULLE, Céline BOILEAU, Julie MASANTE, Séverine DEFORGES, Angélique PERET, Olivier DANOS, Andrew MERCER
-
Publication number: 20220186256Abstract: The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences that confer and/or enhance desired properties. In particular, the invention provides engineered capsid proteins comprising peptide insertions from heterologous proteins inserted within or near variable region IV (VR-IV) of the virus capsid, such that the insertion is surface exposed on the AAV particle. The invention also provides capsid proteins that direct rAAVs to target tissues, in particular, capsid proteins comprising peptides derived from erythropoietin or dynein that are inserted into surface-exposed variable regions and that target rAAVs to retinal tissue and/or neural tissue, including the central nervous system, and deliver therapeutics for treating neurological and/or eye disorders.Type: ApplicationFiled: April 2, 2020Publication date: June 16, 2022Inventors: Olivier Danos, Ye Liu, Andrew Mercer, Samantha Yost, Subha Karumuthil-Melethil, Elad Firnberg
-
Publication number: 20210147854Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: ApplicationFiled: September 24, 2020Publication date: May 20, 2021Inventors: Carlos F. Barbas, Andrew Mercer, Brian M. Lamb, Thomas Gaj
-
Patent number: 10829766Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: GrantFiled: January 23, 2018Date of Patent: November 10, 2020Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
-
Publication number: 20180230474Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques.Type: ApplicationFiled: January 23, 2018Publication date: August 16, 2018Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
-
Patent number: 9902962Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques. The invention provides a chimeric polypeptide. The polypeptide includes: a) a recombinase, nuclease or transcription factor, or fragment thereof; and b) a transcription activator-like effector (TALE) protein.Type: GrantFiled: September 4, 2013Date of Patent: February 27, 2018Assignee: The Scripps Research InstituteInventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
-
Publication number: 20150284728Abstract: Disclosed herein are chimeric polypeptides, including compositions thereof, expression vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors, and methods of the present invention are also useful in gene therapy techniques. The invention provides a chimeric polypeptide. The polypeptide includes: a) a recombinase, nuclease or transcription factor, or fragment thereof; and b) a transcription activator-like effector (TALE) protein.Type: ApplicationFiled: September 4, 2013Publication date: October 8, 2015Inventors: Carlos F. Barbas, III, Andrew Mercer, Brian M. Lamb, Thomas Gaj
-
Patent number: 9075694Abstract: Automating processes in an automation platform. Specifying a program that when executed by the platform implements the process. The program including process description, process components. The description including component initialization instructions having input parameter(s) and initialized component execution instructions having an execution state. Components having an initialization interface, an execution interface, and at least one of simulation instructions and operation instructions. Components characterized by output parameters, and operative upon receiving input parameters via the initialization interface to initialize the component. Initialized components operative upon receiving an execution state via the execution interface to execute the initialized component in accordance with the execution state, and in absence of operation instructions, to return a simulated output in the format of the output parameters in accordance with the simulation instructions.Type: GrantFiled: April 27, 2011Date of Patent: July 7, 2015Inventors: Shane Andrew Mercer, John Matthew Martin, Lindsay Ian Smith
-
Publication number: 20130097096Abstract: Implementing a process in an automation platform. Representing conceptual entities of the process as a nodes in a conceptual graph. Representing process relationships between the conceptual entities as edges between the nodes of the conceptual graph. Transforming the conceptual graph into a structural graph representing an automation design of the process. Transforming the structural graph into implementation artifacts executable on the automation platform. Entities can represent a feature, a constraint, a project phase, a screen, a data item, and a process description. Relationships can include a dependency relationship, a temporal relation-ship, and a parent-child relationship. The transformation into a structural graph being traceable between elements of the conceptual graph and the structural graph. The transformation into a structural graph controlled by a first configuration information. The transformation into a implementation artifacts controlled by a second configuration information.Type: ApplicationFiled: April 27, 2011Publication date: April 18, 2013Applicant: CORE TECHNOLOGY LIMITEDInventors: Shane Andrew Mercer, John Matthew Martin, Lindsay Ian Smith
-
Publication number: 20130055274Abstract: Automating processes in an automation platform. Specifying a program that when executed by the platform implements the process. The program including process description, process components. The description including component initialization instructions having input parameter(s) and initialized component execution instructions having an execution state. Components having an initialization interface, an execution interface, and at least one of simulation instructions and operation instructions. Components characterized by output parameters, and operative upon receiving input parameters via the initialization interface to initialize the component. Initialized components operative upon receiving an execution state via the execution interface to execute the initialized component in accordance with the execution state, and in absence of operation instructions, to return a simulated output in the format of the output parameters in accordance with the simulation instructions.Type: ApplicationFiled: April 27, 2011Publication date: February 28, 2013Inventors: Shane Andrew Mercer, John Matthew Martin, Lindsay Ian Smith
-
Publication number: 20120203744Abstract: Current computing solutions often involve the sharing of data across multiple computer implemented processes. To ensure data integrity throughout the execution environment, an executing process can make a request for data from a Data Provider. In response to the request, the Data Provider can bundle the data and one or more Validation Objects in a Data Object. The Data Object can be passed between executing processes, and at any point in the execution, an executing process can verify the integrity of the data by making a request to the Data Object. To facilitate the passing of Data Objects throughout a heterogeneous execution environment, a Data Object can create a representation of itself specific to the target system. The Data Objects are advantageous in that all of the necessary validation checks are centralized, thus decreasing maintenance costs and the possibility of error.Type: ApplicationFiled: October 8, 2010Publication date: August 9, 2012Inventors: Shane Andrew Mercer, Lindsay Ian Smith, John Mathew Martin